AlloVir (Nasdaq:ALVR) - Cotización, noticias y análisis

Resumen de acción ALVR

Allovir, Inc, una empresa de terapia celular en fase clínica, se dedica a la investigación y el desarrollo de terapias alogénicas de células T multivíricas específicas (VST) para prevenir y tratar enfermedades devastadoras asociadas a virus. Saber más

Análisis fundamental de ALVR
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de AlloVir, Inc.

Cue Biopharma

NasdaqCM:CUE

US$64.6m

Spero Therapeutics

NasdaqGS:SPRO

US$63.2m

Cellectar Biosciences

NasdaqCM:CLRB

US$64.1m

BioAtla

NasdaqGM:BCAB

US$75.9m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de AlloVir
Precios históricos de las acciones
Precio actual de la acción	US$0.55
Máximo en las últimas 52 semanas	US$2.49
Mínimo de 52 semanas	US$0.52
Beta	0.74
1Cambio en 1 mes	-31.52%
Variación en 3 meses	-29.56%
Cambio de 1 año	-64.52%
3Variación en 3 años	-96.99%
Variación en 5 años	n/a
Variación desde la OPV	-97.83%

Noticias y actualizaciones recientes

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Rentabilidad de los accionistas

	ALVR	US Biotechs	Mercado US
7D	-3.4%	2.5%	2.2%
1Y	-64.5%	16.1%	31.6%

Rentabilidad vs. Industria: Los resultados de ALVR fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 16.1% el año pasado.

Rentabilidad vs. Mercado: ALVR obtuvo unos resultados inferiores a los del mercado US, que fueron del 31.6% el año pasado.

Volatilidad de los precios

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	15.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de ALVR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ALVR(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	8	Diana Brainard	www.allovir.com

Allovir, Inc. es una empresa de terapia celular en fase clínica dedicada a la investigación y el desarrollo de terapias alogénicas de células T multivíricas específicas (VST) para prevenir y tratar enfermedades víricas devastadoras. El principal producto de la empresa es el posoleucel, una terapia alogénica de células T multivíricas para tratar el virus BK, el citomegalovirus, el adenovirus, el virus de Epstein-Barr, el herpesvirus humano 6 y el virus JC. Entre sus productos candidatos a desarrollo preclínico y clínico figuran ALVR106 para el virus respiratorio sincitial, la gripe, el virus de la parainfluenza y el metapneumovirus humano; ALVR109 para tratar el SARS-CoV-2 y el COVID-19; ALVR107 para tratar la hepatitis B; y ALVR108.

Resumen de fundamentos de AlloVir, Inc.

¿Cómo se comparan los beneficios e ingresos de AlloVir con su capitalización de mercado?
Estadísticas fundamentales de ALVR
Capitalización bursátil	US$62.92m
Beneficios(TTM)	-US$100.20m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.6x

Ratio precio-beneficio (PE)

¿Está ALVR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ALVR
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$100.20m
Beneficios	-US$100.20m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.88
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ALVR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ALVR

Análisis de riesgos

Competidores de AlloVir, Inc.

NasdaqCM:CUE

US$64.6m

NasdaqGS:SPRO

US$63.2m

NasdaqCM:CLRB

US$64.1m

NasdaqGM:BCAB

US$75.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Recent updates

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock